We need to address this problem.
There clearly needs to be some balance between the exclusivity and the cost savings.
I believe that there are many factors to encouraging and ensuring robust investment in medicines.
As Members of Congress, we typically speak about treating disease in sound bites.
Cures and cutting-edge medicines are of no value if their high costs put them out of reach of the patients who need them...
Let me echo what you said about the hearing and the value of it. I totally agree.
And the problem I have is if we grant exclusivity, we are essentially giving the pharmaceutical free rein to charge what...
For many years, there has been a lot of discussion about how we move our health care system into one of quality and effi...
We believe, and we have made a recommendation along these lines, you can take the elements from that instrument...
I do think that is important to have but, I mean, it is always going to be individual case too, though, obviously.
I am amazed by how much variation exists in the care provided in the post-acute setting.